<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885313</url>
  </required_header>
  <id_info>
    <org_study_id>1406-18-4</org_study_id>
    <nct_id>NCT00885313</nct_id>
  </id_info>
  <brief_title>Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)</brief_title>
  <acronym>EDACN</acronym>
  <official_title>Study of Efficacy and Tolerability of Docosahexaenoic Acid (DHA) on Children Affected by Nonalcoholic Fatty Liver Disease (NAFLD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bambino Gesù Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this interventional study is to evaluate the efficacy and tolerability of
      docosahexaenoic acid (DHA) in children or adolescents with well-characterized and liver
      biopsy confirmed nonalcoholic fatty liver disease (NAFLD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty children or adolescents (4-16 years) with liver biopsy proven NAFLD will be enrolled.
      They will be randomized to treatment with DHA 250 mg/kg/d (n=20), DHA 500 mg/kg/d (n=20), or
      an identical placebo (n=20) given orally for a period of 24 months. All patients will be
      included in a lifestyle intervention program consisting of a diet tailored on the individual
      requirements and physical exercise.

      Patients will undergo a medical evaluation every three months during the 24-month study
      period. Liver biopsy will be performed only at baseline and at the end of treatment.
      Anthropometric analysis, laboratory tests, including liver enzymes and lipids will be
      repeated at 3-month intervals during the 24-month study duration. Ultrasonography and
      Fibroscan of the liver will be repeated at the end of the study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver status by liver biopsy (steatosis and fibrosis)</measure>
    <time_frame>months 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transferase levels</measure>
    <time_frame>month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of triglycerides</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Liver Fibrosis</condition>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>DHA250</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo and lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA250</intervention_name>
    <description>DHA 250 mg/kg/d</description>
    <arm_group_label>DHA250</arm_group_label>
    <other_name>Docosahexaenoic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA500</intervention_name>
    <description>DHA 500 mg/kg/d</description>
    <arm_group_label>DHA500</arm_group_label>
    <other_name>Docosahexaenoic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>placebo</description>
    <arm_group_label>PLA</arm_group_label>
    <other_name>No interventions</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle intervention</intervention_name>
    <description>lifestyle intervention [including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity], for 12 months.</description>
    <arm_group_label>DHA250</arm_group_label>
    <arm_group_label>DHA500</arm_group_label>
    <arm_group_label>PLA</arm_group_label>
    <other_name>Diet and physical activity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persistently elevated serum aminotransferase levels

          -  diffusely echogenic liver on imaging studies suggestive of fatty liver

          -  biopsy consistent with the diagnosis of NAFLD

        Exclusion Criteria:

          -  hepatic virus infections (HCV RNA-PCR negative)

          -  Hepatitis A, B, C, D, E and G

          -  cytomegalovirus and Epstein-Barr virus

          -  alcohol consumption

          -  history of parenteral nutrition

          -  use of drugs known to induce steatosis or to affect body weight and carbohydrate
             metabolism

          -  autoimmune liver disease, metabolic liver disease, Wilson's disease, and
             a-1-antitrypsin-associated liver disease were ruled out using standard clinical,
             laboratory and histological criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerio Nobili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bambino Gesù Children Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bambino Gesù Hospital and Research Institute</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Valerio Nobili, MD</name_title>
    <organization>Bambino Gesù Hospital and Research Institute</organization>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <keyword>fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

